Jupiter Neurosciences, Inc. (JUNS) News
Follow Jupiter Neurosciences, Inc. (JUNS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Jupiter Neurosciences Tumbles on Nasdaq Delisting Notice
Jupiter Neurosciences Tumbles on Nasdaq Delisting Notice
EQUITY | Aug 28, 2026, 10:00 PM UTC
L
Jupiter Neurosciences receives notice of delisting
Jupiter Neurosciences has received a notice of delisting.
EQUITY | Aug 28, 2026, 08:15 PM UTC
H
Jupiter Neurosciences Announces Reverse Stock Split
Jupiter Neurosciences does reverse stock split
EQUITY | Aug 05, 2026, 12:01 PM UTC
L
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences
In this week's "Psychedelic," recurring series focused on psychedelic stock news, looks back on a license agreement, enrollment completion and a patent filing. PHARMALA, JUPITER ENTER LICENSE AGREEMENT: PharmAla Biotech
EQUITY | Jul 23, 2026, 03:07 PM UTC
H
Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket
Shares of Universe Pharmaceuticals Inc (NASDAQ: UPC ) rose sharply in pre-market trading after the company announced it will acquire Best Praise International for $10.75 million. Universe Pharmaceuticals shares jumped 22
RATES | Jun 29, 2026, 11:03 AM UTC
M
12 Health Care Stocks Move
Gainers Universe Pharmaceuticals (NASDAQ: UPC ) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi Therapeutics (NASDAQ: T
EQUITY | Jun 26, 2026, 11:20 PM UTC